SEC Comment Letter 0000000000-23-005731 to Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)
Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)
Date: May 31, 2023 · CIK: 0001614067 · Accession: 0000000000-23-005731
AI Filing Summary & Sentiment
File numbers found in text: 333-272128
Letter
United States securities and exchange commission logo May 31, 2023 Vu Truong Chief Executive Officer Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, California 95032 Re:Aridis Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed on May 22, 2023 File No. 333-272128 Dear Vu Truong: Our initial review of your registration statement indicates that it fails in numerous material respects to comply with the requirements of the Securities Act of 1933, the rules and regulations thereunder, and the requirements of the form. More specifically, your registration statement does not include financial information for the quarterly period ended March 31, 2023, and you are not eligible to incorporate by reference because your Form 10-Q for quarterly period ended March 31, 2023, has not been filed. We will provide more detailed comments relating to your registration statement following our review of a substantive amendment that addresses these deficiencies. Please contact Dillon Hagius at 202-551-7967 or Laura Crotty at 202-551-7614 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeff Fessler
Show Raw Text
United States securities and exchange commission logo
May 31, 2023
Vu Truong
Chief Executive Officer
Aridis Pharmaceuticals, Inc.
983 University Avenue, Bldg. B
Los Gatos, California 95032
Re:Aridis Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed on May 22, 2023
File No. 333-272128
Dear Vu Truong:
Our initial review of your registration statement indicates that it fails in numerous
material respects to comply with the requirements of the Securities Act of 1933, the rules and
regulations thereunder, and the requirements of the form. More specifically, your registration
statement does not include financial information for the quarterly period ended March 31, 2023,
and you are not eligible to incorporate by reference because your Form 10-Q for quarterly period
ended March 31, 2023, has not been filed.
We will provide more detailed comments relating to your registration statement
following our review of a substantive amendment that addresses these deficiencies.
Please contact Dillon Hagius at 202-551-7967 or Laura Crotty at 202-551-7614 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeff Fessler